ABT 8-K Current Reports
ABBOTT LABORATORIES - 306 current reports
ABBOTT LABORATORIES 8-K Report, Executive Changes (Apr 27, 2026)
Abbott Laboratories (ABT) announced significant corporate governance updates following its Annual Shareholder Meeting on April 24, 2026. A key development is the approval of the Abbott Laboratories 2026 Incentive Stock Program, which will replace the previous 2017 program. This new program allows for a broad range of equity-based awards to employees and non-employee directors, with a maximum of 140,000,000 shares available, plus additional shares from the prior program's unused reserves. The program's adoption was overwhelmingly approved by shareholders, indicating strong support for the company's long-term incentive strategy. Additionally, the Board of Directors has been expanded from twelve to thirteen members, effective April 24, 2026. Shareholders also re-elected the entire slate of directors and ratified the appointment of Ernst & Young LLP as the company's auditors. The compensation of named executive officers was approved in an advisory vote, reflecting shareholder confidence in management's remuneration practices. These changes underscore Abbott's commitment to robust governance and aligning executive incentives with shareholder interests.
ABBOTT LABORATORIES 8-K Report, Corporate Update (Apr 17, 2026)
Abbott Laboratories has filed an 8-K report on April 17, 2026, announcing a significant development in a consolidated shareholder derivative lawsuit, "In re Abbott Laboratories Infant Formula Shareholder Derivative Litigation." The company's filing indicates that on April 10, 2026, the court preliminarily approved a proposed settlement in this long-standing litigation concerning certain current and former directors and officers. This preliminary approval is a crucial step towards resolving the six shareholder derivative lawsuits that have been consolidated. While the settlement is not yet final and a final settlement hearing will be scheduled, this development suggests a potential resolution to a significant legal overhang. Investors should note that further details regarding the terms of the settlement will be available in the "Notice of Proposed Settlement of Consolidated Derivative Action, Final Settlement Hearing, and Right to Appear," which is filed as an exhibit to this report. This filing is important for understanding potential legal liabilities and corporate governance matters at Abbott.
ABBOTT LABORATORIES 8-K Report, Financial Results (Apr 16, 2026)
Abbott Laboratories (ABT) has filed an 8-K report on April 16, 2026, to announce its financial results for the first quarter of 2026. The filing primarily directs investors to a furnished press release (Exhibit 99.1) which contains the detailed financial performance and operational updates for the period. While specific GAAP figures are not detailed in the 8-K text itself, the company emphasizes its use of non-GAAP financial measures. These adjusted figures exclude items such as acquisition-related expenses, stock-based compensation acceleration, restructuring costs, certain regulatory costs, and tax adjustments, aiming to provide a clearer view of ongoing business performance. Management believes these non-GAAP measures offer valuable insights into operational trends, complementing the standard GAAP reporting.
ABBOTT LABORATORIES 8-K Report, Corporate Update (Mar 23, 2026)
Abbott Laboratories (ABT) has announced the successful completion of its acquisition of Exact Sciences Corporation, a significant move that closed on March 23, 2026. This strategic acquisition, executed through a merger agreement finalized on November 19, 2025, integrates Exact Sciences into Abbott's structure as a wholly owned subsidiary. The transaction involved an all-cash payout of $105.00 per share for Exact Sciences common stock, a substantial financial commitment by Abbott. This acquisition is expected to be a transformative event for Abbott, likely bolstering its position in the diagnostics and healthcare markets, particularly in areas where Exact Sciences has a strong presence, such as cancer screening and genomic testing. Investors should closely monitor the integration process and the impact on Abbott's future revenue streams and market share, as this deal represents a major step in the company's growth strategy.
ABBOTT LABORATORIES 8-K Report, Material Agreement (Mar 9, 2026)
Abbott Laboratories (ABT) has announced the successful completion of a significant public offering of senior notes, raising a total of $20 billion. This substantial debt issuance comprises various tranches with different maturities and interest rates, ranging from floating rate notes due in 2029 to fixed-rate notes maturing in 2066. The primary purpose of this financing is to fund the acquisition of Exact Sciences Corporation, a strategic move that underscores Abbott's commitment to expanding its presence in the diagnostics and oncology sectors. While the offering provides the necessary capital for this major acquisition, investors should be aware of the conditional nature of the debt. The indenture includes a special mandatory redemption clause. If the Exact Sciences acquisition does not close by a specified date (currently the later of February 17, 2027, or an agreed-upon later date), or if Abbott decides not to proceed with the acquisition, the company will be obligated to redeem all outstanding notes at a premium (101% of principal plus accrued interest). This structure highlights the importance of the Exact Sciences deal for both Abbott's strategic direction and its financing obligations.
ABBOTT LABORATORIES 8-K Report, Material Agreement (Feb 26, 2026)
Abbott Laboratories (ABT) has filed an 8-K report detailing a significant material definitive agreement. On February 23, 2026, the company entered into a pricing agreement to issue and sell $20 billion in aggregate principal amount of senior notes. These notes comprise various fixed-rate tranches with maturities ranging from 2029 to 2066, as well as a floating rate note due in 2029. The offering is being conducted under a shelf registration statement and will be made pursuant to a prospectus supplement filed on February 25, 2026. The primary use of the net proceeds from this substantial debt offering is to fund the consideration for the acquisition of Exact Sciences Corporation. Additionally, proceeds will be used to repay Exact Sciences' existing indebtedness, cover associated fees and expenses, and for general corporate purposes, which may include further debt repayment. The closing of this notes offering is anticipated on March 9, 2026, subject to standard closing conditions.
ABBOTT LABORATORIES 8-K Report, Bylaw Amendment (Feb 20, 2026)
Abbott Laboratories (ABT) has filed a Current Report (8-K) on February 20, 2026, primarily detailing an amendment to its Board of Directors size. Effective April 24, 2026, the Board will be reduced from thirteen to twelve members. This change reflects a strategic decision by the Board of Directors and is a standard corporate governance adjustment. While not directly impacting current financial performance, changes in board composition can signal future strategic shifts or governance refinements. Investors should monitor any subsequent communications for insights into the rationale behind this reduction and its potential implications for board oversight and decision-making processes.
ABBOTT LABORATORIES 8-K Report, Financial Results (Jan 22, 2026)
Abbott Laboratories (ABT) has filed an 8-K report on January 21, 2026, to announce its fourth quarter and full-year 2025 financial results. The report highlights that the company's earnings release, furnished as an exhibit, will present both GAAP and non-GAAP financial measures. Investors should pay close attention to these non-GAAP figures as Abbott's management utilizes them to provide a clearer view of ongoing operational performance, excluding items such as acquisition-related expenses, restructuring costs, legal reserves, and intangible amortization. The company emphasizes that these non-GAAP measures are intended to offer investors greater visibility into the underlying business performance by adjusting for factors that management considers unusual or unpredictable. While these adjustments aim to facilitate better evaluation of operational trends, investors are advised to consider these non-GAAP measures alongside, and not as a substitute for, the GAAP financial measures. The filing also includes the press release and an interactive data file for enhanced analysis.
ABBOTT LABORATORIES 8-K Report, Executive Changes (Dec 12, 2025)
Abbott Laboratories (ABT) filed an 8-K on December 12, 2025, primarily announcing a change in its Board of Directors composition and size. The company appointed Nita Ahuja, M.D. to its Board, effective December 12, 2025. This appointment increases the total number of directors from twelve to thirteen. The amendment to the company's bylaws formalizes this increase, reflecting a strategic expansion of its governance structure. The filing also notes the amended and restated By-Laws of Abbott Laboratories, effective December 12, 2025, as an exhibit, indicating these governance changes are now officially documented.
ABBOTT LABORATORIES 8-K Report, Temporary Suspension of Trading Under Employee Benefit Plans (Nov 21, 2025)
Abbott Laboratories (ABT) has filed an 8-K to announce a temporary trading suspension, commonly known as a "blackout period," affecting its employee benefit plans. This suspension is due to significant administrative changes within the Abbott Laboratories Stock Retirement Plan (U.S. Plan) and the Abbott Laboratories Stock Retirement Plan (Puerto Rico). These changes include the transition of recordkeepers, trustees for certain U.S. Plan funds, and custodians for certain P.R. Plan funds. Investors should note that while this impacts plan participants' ability to transact within their retirement accounts, it does not directly affect the company's ongoing business operations or its publicly traded stock in the open market. The blackout period is scheduled to commence on December 24, 2025, and is expected to conclude by the week of January 11, 2026. During this time, participants will be unable to make changes to their contributions, investments, loans, withdrawals, or distributions. The company has formally notified its directors and executive officers of these restrictions as required by Sarbanes-Oxley Act regulations.
ABBOTT LABORATORIES 8-K Report, Material Agreement (Nov 20, 2025)
Abbott Laboratories (ABT) announced a significant strategic move by entering into a definitive agreement to acquire Exact Sciences Corporation for $105.00 per share in cash. This acquisition, structured as a merger where Exact Sciences will become a wholly-owned subsidiary of Abbott, represents a substantial investment by Abbott into the diagnostics and cancer screening market. The transaction is subject to customary closing conditions, including shareholder approval from Exact Sciences and regulatory clearance, such as the Hart-Scott-Rodino Antitrust Improvements Act. This deal is expected to bolster Abbott's presence in precision medicine and oncology. The financial implications include a commitment of up to $20 billion in bridge loans from Morgan Stanley Senior Funding, Inc. to finance the transaction. Abbott has scheduled an investor conference call to discuss the merger, indicating its strategic importance and the company's intent to provide detailed insights into the rationale and expected benefits of this acquisition.
ABBOTT LABORATORIES 8-K Report, Financial Results (Oct 15, 2025)
Abbott Laboratories (ABT) has filed an 8-K report detailing its financial results for the third quarter of 2025, announced on October 15, 2025. The filing includes a press release that presents both GAAP and non-GAAP financial measures. Investors should pay close attention to the company's use of non-GAAP figures, which exclude items such as acquisition-related expenses, restructuring costs, contingent consideration adjustments, certain regulatory costs, and tax-related adjustments. Abbott's management utilizes these non-GAAP measures to offer a clearer view of ongoing operational performance by adjusting for unusual or unpredictable factors. While these measures are intended to provide greater visibility into core business results, it is crucial for investors to consider them alongside the company's GAAP-reported financials. The press release, furnished as an exhibit, will contain the specific details of these financial outcomes and the reconciliation of non-GAAP to GAAP figures.
ABBOTT LABORATORIES 8-K Report, Financial Results (Jul 17, 2025)
Abbott Laboratories (ABT) has filed an 8-K report detailing its financial results for the second quarter of 2025, announced on July 17, 2025. The report primarily incorporates a press release that provides a non-GAAP view of the company's earnings. Investors should note that Abbott utilizes non-GAAP financial measures, which exclude items such as acquisition-related expenses, restructuring costs, fair value adjustments to contingent consideration, certain regulatory costs, prior tax benefit adjustments, and intangible amortization. The company states these measures offer greater visibility into ongoing business performance and are used internally for assessment. While the 8-K does not provide specific Q2 2025 financial figures within the report itself, it directs investors to an accompanying press release (Exhibit 99.1) for detailed results and analysis. Investors are advised to consider these non-GAAP figures alongside the company's GAAP financial measures, as the non-GAAP metrics are presented for informational purposes to aid in evaluating operational performance and should not be viewed as a substitute for GAAP-based reporting.
ABBOTT LABORATORIES 8-K Report, Executive Changes (May 1, 2025)
Abbott Laboratories (ABT) has filed a Form 8-K to report a significant executive change. Hubert L. Allen, Executive Vice President, General Counsel, and Secretary, has announced his intention to retire from the company. Mr. Allen's departure marks the end of an era for a key leadership position within Abbott, and the company will be undergoing a transition period to fill his role. While the filing itself does not provide details on a successor or the exact timeline for Mr. Allen's retirement, investors should monitor future communications from Abbott for updates on the leadership transition. The General Counsel and Secretary role is critical for corporate governance and legal oversight, making any changes in this position a point of focus for stakeholders concerned with the company's regulatory compliance and strategic direction.
ABBOTT LABORATORIES 8-K Report, Shareholder Vote Results (Apr 28, 2025)
Abbott Laboratories (ABT) has filed an 8-K detailing the outcomes of its Annual Meeting of Shareholders held on April 25, 2025. The primary focus of this filing is the voting results on key corporate matters. Notably, all proposed directors were re-elected to the Board, with the vast majority of votes cast in favor of each nominee. Additionally, shareholders overwhelmingly ratified the appointment of Ernst & Young LLP as the company's independent auditor for the upcoming fiscal year, indicating strong confidence in the current audit process and oversight. The advisory vote on executive compensation also passed, with nearly 90% of cast votes approving the compensation of named executive officers. While this vote is non-binding, it signals shareholder satisfaction with the company's remuneration policies. The filing provides detailed breakdowns of votes for, against, abstentions, and broker non-votes for each resolution, offering transparency into shareholder sentiment.
ABBOTT LABORATORIES 8-K Report, Financial Results (Apr 16, 2025)
Abbott Laboratories (ABT) has filed an 8-K report on April 16, 2025, announcing its first-quarter 2025 financial results. The filing primarily references a press release (Exhibit 99.1) that details these results. Investors should note that Abbott utilizes non-GAAP financial measures to present its performance, adjusting for items such as acquisition-related expenses, restructuring costs, contingent consideration adjustments, impairment charges, certain regulatory costs, tax benefits/expenses, and intangible amortization. The company states that these non-GAAP measures are intended to provide greater visibility into ongoing business performance and are used internally by management, but investors are cautioned to consider these in conjunction with, not as a substitute for, GAAP measures.
ABBOTT LABORATORIES 8-K Report, Financial Results (Jan 22, 2025)
Abbott Laboratories (ABT) has filed an 8-K report on January 22, 2025, announcing its financial results for the fourth quarter and full year 2024. The report primarily references a press release (Exhibit 99.1) that details these results. Investors should note that Abbott utilizes non-GAAP financial measures to present its performance, adjusting for items such as acquisition and divestiture expenses, restructuring costs, fair value adjustments, impairment charges, regulatory costs, tax-related adjustments, and intangible amortization. The company states that these non-GAAP measures offer better insight into ongoing business performance as assessed by management, but investors are cautioned to consider them alongside GAAP measures.
ABBOTT LABORATORIES 8-K Report, Executive Changes (Nov 15, 2024)
Abbott Laboratories (ABT) has filed an 8-K report detailing the extension of its Change in Control Agreements with named executive officers. These agreements, originally set to expire on December 31, 2024, have been extended through December 31, 2026, following Abbott's notification to its executives on November 12, 2024. This extension is a proactive measure that provides continued stability and security for key leadership during a potentially transitional period, ensuring continuity in strategic direction and operations.
ABBOTT LABORATORIES 8-K Report, Financial Results (Oct 16, 2024)
Abbott Laboratories (ABT) has filed an 8-K report on October 16, 2024, to announce its third-quarter 2024 financial results. The report primarily references a press release issued on October 16, 2024, which details these results and includes the use of various non-GAAP financial measures. Investors should note that these non-GAAP measures are presented to offer a clearer view of ongoing business performance by excluding items such as acquisition-related expenses, restructuring costs, and fair value adjustments. While Abbott's management believes these non-GAAP metrics provide valuable insights, they are intended to supplement, not replace, GAAP-based financial measures. The filing highlights the company's emphasis on providing transparency into its operational performance beyond standard accounting practices, allowing for a better evaluation of core business trends. Investors are encouraged to review the provided press release for the specific financial figures and further details on the non-GAAP adjustments.
ABBOTT LABORATORIES 8-K Report, Financial Results (Jul 18, 2024)
Abbott Laboratories (ABT) has filed an 8-K report on July 18, 2024, to announce its second quarter 2024 financial results. The filing primarily incorporates a press release containing the detailed financial performance for the quarter. Investors should note that Abbott utilizes non-GAAP financial measures alongside GAAP measures to provide a clearer view of ongoing operational performance. These non-GAAP metrics exclude items such as acquisition-related expenses, restructuring costs, and amortization, which management believes offer better insight into the company's core business operations.
ABBOTT LABORATORIES 8-K Report, Executive Changes (May 1, 2024)
Abbott Laboratories (ABT) announced the upcoming retirement of its Executive Vice President, Finance, Robert E. Funck, Jr., effective July 1, 2024. Mr. Funck's departure follows a distinguished 36-year career with the company. This transition marks the end of an era for a key financial executive, and investors will be keen to understand the succession plan and the impact on the company's financial leadership and strategy moving forward.
ABBOTT LABORATORIES 8-K Report, Shareholder Vote Results (Apr 29, 2024)
This 8-K filing from Abbott Laboratories (ABT) reports on the outcomes of its Annual Meeting of Shareholders held on April 26, 2024. The primary focus of the filing is the voting results on key corporate matters. Investors will note the overwhelming support for the re-election of the entire Board of Directors, with all nominees receiving a significant majority of the votes cast. The appointment of Ernst & Young LLP as the company's independent auditor was also overwhelmingly ratified. Finally, shareholders provided an advisory vote on the compensation of named executive officers, which passed with a strong majority, though this vote is non-binding. Overall, the results indicate continued shareholder confidence in the current leadership and governance structure of Abbott Laboratories. The robust support for the Board and auditors suggests a stable operating environment and alignment between management and its shareholders on fundamental corporate governance matters. While the executive compensation vote is advisory, the high approval rate is generally viewed as positive feedback on the company's pay practices.
ABBOTT LABORATORIES 8-K Report, Financial Results (Apr 17, 2024)
Abbott Laboratories (ABT) has filed an 8-K report on April 17, 2024, to announce its first-quarter 2024 financial results. The filing primarily incorporates a press release detailing these results and highlights the use of non-GAAP financial measures. These non-GAAP measures exclude items such as acquisition-related expenses, restructuring costs, fair value adjustments, impairment charges, certain regulatory and tax items, and intangible amortization. Management utilizes these non-GAAP figures to offer investors a clearer view of ongoing operational performance, as they believe these adjustments provide better insight into the core business's results, aligning with internal performance assessments. While Abbott emphasizes the utility of these non-GAAP measures for evaluating business performance, it also strongly advises investors to consider them alongside, and not as a replacement for, standard GAAP financial metrics.
ABBOTT LABORATORIES 8-K Report, Material Agreement (Jan 29, 2024)
Abbott Laboratories (ABT) has entered into a new Five Year Credit Agreement, establishing a $5 billion unsecured revolving credit facility. This new agreement replaces a similar facility that was set to mature in November 2025. Notably, there were no outstanding borrowings under the previous agreement at the time of its termination, and as of the filing date, there are no outstanding borrowings under the new facility. This action indicates Abbott's proactive approach to maintaining strong liquidity and financial flexibility. The new credit agreement allows for borrowings based on either a base rate or SOFR rate, with interest margins tied to Abbott's credit ratings. The company also acknowledges customary fees associated with such agreements. The termination of the old agreement and the establishment of the new one are standard financial management practices, ensuring continued access to capital for operational needs or strategic initiatives without immediate financial commitment.
ABBOTT LABORATORIES 8-K Report, Financial Results (Jan 24, 2024)
Abbott Laboratories (ABT) has filed an 8-K report on January 24, 2024, announcing its fourth quarter and full-year 2023 financial results. The report primarily references a press release (Exhibit 99.1) that details these results. Investors should note that Abbott's earnings release includes both GAAP and non-GAAP financial measures. The company uses non-GAAP measures, which exclude various items such as acquisition-related expenses, restructuring costs, voluntary recall expenses, impairment charges, and certain tax adjustments, to provide a clearer view of ongoing operational performance. While the specific financial figures are contained within the referenced press release, the 8-K filing serves as the official notification of their release and provides context for the non-GAAP adjustments made by Abbott management. Management believes these non-GAAP measures offer valuable insights into the core business performance and are used internally for performance monitoring. Investors are advised to consider these non-GAAP figures alongside GAAP measures for a comprehensive understanding of the company's financial health.
ABBOTT LABORATORIES 8-K Report, Financial Results (Oct 18, 2023)
Abbott Laboratories (ABT) filed an 8-K on October 17, 2023, to report its financial results for the third quarter of 2023, which were announced on October 18, 2023. The filing primarily incorporates a press release detailing these results. Investors should note that Abbott, as is common practice, utilizes both GAAP (Generally Accepted Accounting Principles) and non-GAAP financial measures. The non-GAAP measures adjust for items such as acquisition-related expenses, restructuring costs, voluntary recalls, impairment charges, and tax adjustments, which management believes offer better insight into ongoing operational performance. While these non-GAAP figures aim to provide a clearer view of the core business, it is crucial for investors to consider them alongside, and not as a substitute for, the standard GAAP measures. The press release, furnished as Exhibit 99.1, will contain the detailed financial performance data. Investors seeking specific performance metrics, including revenue, earnings, and segment-specific results, should refer to this accompanying press release, as the 8-K itself mainly serves as a notification of the earnings release.
ABBOTT LABORATORIES 8-K/A Report, Shareholder Vote Results (Sep 1, 2023)
This 8-K filing is an amendment to a previous report filed on May 2, 2023, concerning Abbott Laboratories' (ABT) Annual Meeting of Shareholders held on April 28, 2023. The primary purpose of this amendment is to correct a typographical error in the reported number of shares cast against Michael F. Roman, a key executive. The amendment clarifies the voting results for Mr. Roman, providing updated figures for votes cast for, against, abstentions, and broker non-votes. For investors, this filing is largely administrative and confirms the original outcome of the shareholder vote regarding Mr. Roman's re-election. While the correction itself is minor and does not alter the overall outcome of the shareholder vote, it demonstrates Abbott's commitment to accurate reporting. The overwhelming majority of votes were cast in favor of Mr. Roman, indicating continued shareholder confidence in leadership.
ABBOTT LABORATORIES 8-K Report, Financial Results (Jul 20, 2023)
Abbott Laboratories (ABT) filed an 8-K on July 20, 2023, to report its second-quarter 2023 financial results. The report primarily furnished a press release detailing the company's performance. Investors should note that Abbott, like many companies, utilizes non-GAAP financial measures to present its results, adjusting for items such as acquisition-related expenses, restructuring costs, voluntary recall expenses, impairment charges, and tax-related adjustments. Management believes these measures offer a clearer view of ongoing operational performance, supplementing the standard GAAP reporting.
ABBOTT LABORATORIES 8-K Report, Executive Changes (Jun 12, 2023)
Abbott Laboratories (ABT) has announced a significant leadership transition within its finance department, effective September 1, 2023. This 8-K filing details the appointments of key finance executives, including Robert E. Funck, Jr. as Executive Vice President, Finance. Philip P. Boudreau will step into the role of Senior Vice President, Finance and Chief Financial Officer, continuing to report to Mr. Funck. John A. McCoy, Jr. has been appointed Vice President, Controller. These appointments reflect a strategic alignment of financial leadership within Abbott. Mr. Boudreau's long tenure and extensive experience within the company, including his recent role as Vice President, Controller, position him well for his new CFO responsibilities. Mr. McCoy's background, including his recent role as Vice President, Treasurer, also provides a solid foundation for his new position as Controller. Investors should monitor how these leadership changes impact financial strategy and execution moving forward.
ABBOTT LABORATORIES 8-K/A Report, Shareholder Vote Results (Jun 9, 2023)
This 8-K/A filing from Abbott Laboratories serves as an amendment to their previous 8-K filing dated May 2, 2023, which reported on the outcomes of their Annual Meeting of Shareholders held on April 28, 2023. The key update relates to the compensation of named executive officers. Following the shareholder vote and in line with the Board of Directors' recommendation, Abbott has confirmed that an advisory vote on executive compensation will be conducted annually going forward. This decision means shareholders will have an ongoing opportunity to provide their non-binding input on the compensation packages of Abbott's top executives. While advisory in nature, these votes are closely watched by the Board and management and can influence future compensation decisions. Investors should note that this is a procedural update regarding the frequency of the "say-on-pay" vote, rather than a change in compensation policy itself.
ABBOTT LABORATORIES 8-K Report, Shareholder Vote Results (May 2, 2023)
Abbott Laboratories (ABT) filed an 8-K on May 2, 2023, detailing the results of its Annual Meeting of Shareholders held on April 28, 2023. The report confirms the election of all nominated directors to the Board and the ratification of Ernst & Young LLP as the company's independent auditor. Shareholder approval was also given for the advisory vote on executive compensation and for holding this vote annually. Importantly, several shareholder proposals were voted down. These included proposals related to lowering the threshold for calling special meetings, requiring an independent board chairman, disclosing lobbying expenditures, and adjusting executive compensation metrics to exclude legal/compliance costs. The overwhelming support for the company's nominees and auditor, along with the rejection of these specific shareholder initiatives, signals continued confidence from the majority of shareholders in the current governance and operational strategies of Abbott Laboratories.
ABBOTT LABORATORIES 8-K Report, Financial Results (Apr 19, 2023)
Abbott Laboratories (ABT) reported its first quarter 2023 financial results on April 19, 2023. The company provided a press release, furnished as Exhibit 99.1, detailing its performance. Notably, the report highlights Abbott's use of non-GAAP financial measures, which exclude items such as acquisition-related expenses, restructuring actions, voluntary recall costs, certain regulatory costs, and tax-related adjustments. Management believes these non-GAAP measures offer investors better insight into ongoing business performance by removing unusual or unpredictable factors, similar to internal assessments. While the specific financial figures are detailed in the press release (Exhibit 99.1), this 8-K filing primarily serves to announce the results and reference the accompanying press release. Investors are advised to consider these non-GAAP measures alongside traditional GAAP figures for a comprehensive understanding of Abbott's financial health and operational efficiency.
ABBOTT LABORATORIES 8-K Report, Bylaw Amendment (Feb 17, 2023)
Abbott Laboratories (ABT) has filed an 8-K report primarily detailing an amendment to its bylaws concerning the size of its Board of Directors. Effective April 28, 2023, the Board of Directors will be reduced from thirteen members to twelve persons. This change is administrative and does not appear to be tied to any immediate strategic shifts or financial performance indicators disclosed in this specific filing.
ABBOTT LABORATORIES 8-K Report, Financial Results (Jan 25, 2023)
Abbott Laboratories (ABT) has filed an 8-K report on January 25, 2023, to announce its fourth quarter and full year 2022 financial results. The filing primarily includes a press release containing these results. Investors should note that Abbott, like many companies, utilizes non-GAAP financial measures to provide a clearer view of ongoing operational performance, excluding items such as acquisition-related expenses, restructuring costs, voluntary recalls, certain litigation, and tax adjustments. While these non-GAAP measures aim to offer better insight into the core business performance as assessed by management, investors are reminded to consider these alongside the Generally Accepted Accounting Principles (GAAP) measures. The press release itself, furnished as an exhibit, contains the detailed financial performance data for the periods ending December 31, 2022. Investors seeking specific figures on revenue, earnings, and segment performance should refer to this press release.
ABBOTT LABORATORIES 8-K Report, Bylaw Amendment (Dec 9, 2022)
Abbott Laboratories (ABT) filed an 8-K on December 9, 2022, to report the amendment and restatement of its by-laws, effective immediately. These changes primarily focus on updating and clarifying the procedural mechanics and information requirements for shareholder nominations of directors and shareholder proposals at meetings. This includes specific provisions related to Rule 14a-19 under the Exchange Act, which governs proxy access. The amendments also address special meetings, the powers of the Board and meeting Chair, and include other ministerial, conforming, and gender-neutrality updates. While these amendments are primarily procedural and do not alter Abbott's financial performance or strategic direction, they are important for shareholders to understand as they impact how shareholder actions can be brought forth and managed at company meetings. Investors should be aware that these changes are designed to ensure compliance with evolving regulations and to streamline meeting governance.
ABBOTT LABORATORIES 8-K Report, Executive Changes (Oct 21, 2022)
Abbott Laboratories (ABT) has filed an 8-K report on October 21, 2022, primarily addressing the extension of its Change in Control Agreements with its named executive officers. These agreements, originally set to expire on December 31, 2022, have been extended for an additional two years, now through December 31, 2024. This extension provides continuity and stability for key leadership during a period that could involve significant corporate events. For investors, this action signals Abbott's commitment to retaining its executive team and maintaining a stable leadership structure. The extension of these agreements suggests management's confidence in the company's future and its ongoing strategies. While the filing itself does not disclose specific financial performance or new business initiatives, it reassures stakeholders about leadership continuity, which is often a positive indicator for long-term strategic execution and stability.
ABBOTT LABORATORIES 8-K Report, Financial Results (Oct 19, 2022)
Abbott Laboratories (ABT) filed an 8-K on October 19, 2022, to report its third-quarter 2022 financial results. The filing primarily consists of a press release detailing these results and is furnished as an exhibit. Investors should note that Abbott utilizes non-GAAP financial measures, which exclude certain items such as acquisition-related expenses, restructuring costs, voluntary recalls, litigation, and impairment charges, among others. The company states that these adjustments provide a clearer view of ongoing business performance, aligning with how management internally assesses results.
ABBOTT LABORATORIES 8-K Report, Executive Changes (Sep 15, 2022)
Abbott Laboratories (ABT) filed an 8-K on September 15, 2022, primarily announcing two key governance changes. The company appointed Claire Babineaux-Fontenot to its Board of Directors, effective September 15, 2022. This addition brings new expertise and perspectives to the board's oversight. In conjunction with this appointment, Abbott's Board of Directors also amended its bylaws to increase the size of the board from twelve to thirteen members. This adjustment provides the necessary capacity for the new director and allows for potential future expansion. Investors should view these as routine corporate governance actions aimed at strengthening the board's composition and effectiveness.
ABBOTT LABORATORIES 8-K Report, Financial Results (Jul 20, 2022)
Abbott Laboratories (ABT) filed an 8-K on July 20, 2022, to announce its second quarter 2022 financial results. The filing primarily furnished a press release detailing these results. Investors should note that Abbott utilizes non-GAAP financial measures in its reporting, which exclude items such as acquisition-related expenses, restructuring costs, voluntary recall expenses, and certain litigation and tax items. The company asserts that these non-GAAP measures provide greater visibility into ongoing business performance and are used internally for performance assessment.
ABBOTT LABORATORIES 8-K Report, Shareholder Vote Results (May 2, 2022)
This 8-K filing from Abbott Laboratories details the outcomes of its Annual Meeting of Shareholders held on April 29, 2022. Key investor-focused information includes the overwhelming re-election of the entire Board of Directors and the ratification of Ernst & Young LLP as the company's auditor. Shareholders also approved the compensation of named executive officers in an advisory vote. The filing also outlines several shareholder proposals that were rejected by the majority of votes cast, including proposals related to special meeting thresholds, independent board chair, Rule 10b5-1 plans, lobbying expenditures, and antimicrobial resistance reporting. From an investor's perspective, the broad support for the board and auditor indicates a level of confidence in current management and governance. The rejection of most shareholder proposals suggests that the board's current strategies and policies are favored by the majority of shareholders, or at least that the proposals did not garner sufficient support to pass. The advisory vote on executive compensation passing with over 91% approval is a positive signal regarding shareholder alignment on pay practices.
ABBOTT LABORATORIES 8-K Report, Financial Results (Apr 20, 2022)
Abbott Laboratories (ABT) filed an 8-K on April 20, 2022, to report its first quarter 2022 financial results. The filing primarily serves to furnish the press release detailing these results, which was issued on the same day. Investors should note that Abbott utilizes non-GAAP financial measures to provide additional insight into its operational performance. These measures adjust for specific items such as acquisition-related expenses, restructuring costs, voluntary recalls, and amortization of intangibles, aiming to offer a clearer view of ongoing business performance as assessed by management.
ABBOTT LABORATORIES 8-K Report, Bylaw Amendment (Feb 22, 2022)
Abbott Laboratories (ABT) has filed an 8-K report primarily detailing an amendment to its bylaws concerning the size of its Board of Directors. Effective April 29, 2022, the Board of Directors will be reduced from thirteen to twelve members. This change, approved by the Board of Directors on February 18, 2022, revises Article III, Section 2 of Abbott's bylaws. While this is a procedural change related to corporate governance, investors should note that such adjustments in board size can sometimes precede or accompany other strategic shifts, though no specific strategic implications are mentioned in this filing. The filing also includes updated bylaws and cover page interactive data. The report was signed by Robert E. Funck, Jr., Executive Vice President, Finance and Chief Financial Officer.
ABBOTT LABORATORIES 8-K Report, Regulation FD Disclosure (Feb 18, 2022)
Abbott Laboratories (ABT) filed an 8-K on February 18, 2022, disclosing a proactive, voluntary recall of Similac-brand powder infant formulas manufactured at its Sturgis, Michigan facility. This recall primarily affects products distributed in the U.S. and Canada. While the company is confirming its previously issued full-year 2022 guidance for adjusted diluted earnings per share from continuing operations at $4.70 or more, it anticipates a one-time expense in the first quarter of 2022 related to recall expenses, including inventory destruction. Despite these recall-related costs, Abbott does not expect the expenses to have a material impact on its consolidated financial statements. The company has issued a press release to inform consumers about the recall. Investors should note that while the company is reiterating its full-year earnings guidance, the undisclosed but expected expenses in Q1 2022 related to this recall warrant attention for short-term financial impacts.
ABBOTT LABORATORIES 8-K Report, Financial Results (Jan 26, 2022)
Abbott Laboratories (ABT) filed an 8-K on January 26, 2022, to announce its fourth quarter and full-year 2021 financial results. The filing primarily incorporates a press release (Exhibit 99.1) that details these results. Investors should note that Abbott, as is common practice, utilizes non-GAAP financial measures alongside GAAP. These non-GAAP measures are adjusted to exclude items considered unusual or unpredictable, such as acquisition-related expenses, restructuring costs, litigation, and others, with the aim of providing a clearer view of ongoing operational performance. Management uses these measures internally for performance assessment and believes they offer valuable insights to investors. While the specific financial figures are detailed in the furnished press release, the 8-K itself serves as the official notification of their release. Investors are encouraged to review the referenced press release for comprehensive details on revenue, earnings, and other key performance indicators for Q4 and FY2021. The CFO, Robert E. Funck, Jr., signed the report, affirming the company's disclosures.
ABBOTT LABORATORIES 8-K Report, Executive Changes (Dec 13, 2021)
Abbott Laboratories (ABT) has filed an 8-K report on December 13, 2021, primarily to announce the decision of Roxanne S. Austin not to stand for re-election to the Board of Directors at the company's 2022 annual shareholders meeting. This departure, effective after her current term ends in April 2022, is a significant event concerning board composition. While this filing does not disclose any operational or financial performance changes, investors should note the upcoming change in board membership. Ms. Austin's decision, communicated on December 9, 2021, marks the end of her tenure, and the company will need to elect a successor at the upcoming meeting. The report is signed by Robert E. Funck, Jr., Executive Vice President, Finance, and Chief Financial Officer, indicating official company acknowledgment.
ABBOTT LABORATORIES 8-K Report, Executive Changes (Dec 10, 2021)
Abbott Laboratories (ABT) announced a significant leadership transition in an 8-K filing dated December 10, 2021. Miles D. White has stepped down as Executive Chairman of the Board and as a director, effective December 10, 2021. In a concurrent move, the Board of Directors appointed Robert B. Ford, who currently serves as President, CEO, and a director, to the additional role of Chairman of the Board. This change consolidates key leadership positions under Mr. Ford, signaling continuity and a unified vision for the company's future direction. In addition to the leadership changes, Abbott's Board of Directors also amended and restated its by-laws. These amendments include a reduction in the size of the Board of Directors from fourteen to thirteen members. Furthermore, the by-laws were updated to comply with recent changes in Illinois law, allowing for shareholder meetings to be conducted solely through remote communication. These actions reflect the company's adaptation to evolving corporate governance best practices and regulatory requirements.
ABBOTT LABORATORIES 8-K Report, Financial Results (Oct 20, 2021)
Abbott Laboratories (ABT) filed an 8-K on October 20, 2021, to announce its third-quarter 2021 financial results. The report primarily serves to furnish a press release detailing these results. Investors should note that while the press release presents both GAAP and non-GAAP financial measures, Abbott emphasizes its non-GAAP figures, which exclude certain items like acquisition-related expenses, restructuring costs, and amortization. These adjustments are presented to offer a clearer view of ongoing operational performance as assessed by management. The company is providing these non-GAAP figures to allow investors to better evaluate the core business performance, excluding unusual or unpredictable factors. While these measures are considered useful by Abbott's management, investors are advised to consider them alongside GAAP measures and not as a substitute. The filing also includes the press release as an exhibit and notes the CFO's signature.
ABBOTT LABORATORIES 8-K Report, Executive Changes (Sep 1, 2021)
Abbott Laboratories (ABT) filed an 8-K report on September 1, 2021, detailing changes to its Board of Directors and bylaws. The most significant event for investors is the appointment of Patricia P. Gonzalez to the Board of Directors, effective August 30, 2021. This appointment may signal a strategic direction or bring valuable expertise to the company's governance and decision-making processes. Additionally, the company amended its bylaws to increase the size of its Board of Directors from thirteen to fourteen members, also effective August 30, 2021. This expansion could be in anticipation of future growth, diversification of skills on the board, or a response to evolving corporate governance best practices. Investors should monitor future communications for insights into the specific contributions Ms. Gonzalez is expected to make and the broader implications of the board expansion.
ABBOTT LABORATORIES 8-K Report, Financial Results (Jul 22, 2021)
Abbott Laboratories (ABT) filed an 8-K on July 22, 2021, to report its second quarter 2021 financial results. The filing primarily references a press release (Exhibit 99.1) which details the company's operational and financial performance for the period. Investors should note that Abbott utilizes non-GAAP financial measures in its reporting, adjusting for items such as acquisition-related expenses, restructuring costs, litigation, and other unusual or unpredictable factors. These non-GAAP measures are presented to offer a clearer view of the ongoing business performance as assessed by management, and are intended to supplement, not replace, GAAP-based reporting. While the 8-K itself is procedural, the accompanying press release is the crucial document for understanding Abbott's quarterly performance. Investors will need to refer to Exhibit 99.1 for specific financial figures, including revenue, earnings, and segment performance. The company's use of non-GAAP measures, while common practice, means investors should carefully review both the GAAP and non-GAAP figures to gain a comprehensive understanding of the company's financial health and operational efficiency.
ABBOTT LABORATORIES 8-K Report, Exit or Disposal Costs (Jun 3, 2021)
Abbott Laboratories (ABT) has filed an 8-K report detailing a significant restructuring plan impacting its COVID-19 diagnostic test manufacturing network. This plan is a direct response to evolving market dynamics, including reduced COVID-19 cases, accelerated vaccine rollouts, and updated guidance on testing for vaccinated individuals. The company anticipates incurring substantial pre-tax costs, estimated between $550 million and $700 million, primarily during the remainder of 2021, with a significant portion expected in the second quarter. These costs will encompass asset write-downs, inventory charges, and other exit-related expenses such as contract cancellations and employee costs. A notable portion of these charges ($320 million to $400 million) are non-cash. The company also disclosed an update to its 2021 financial outlook, providing non-GAAP adjusted diluted earnings per share, which excludes expenses related to restructuring and acquisitions. Investors should note the impact of these restructuring costs on near-term profitability while also considering the forward-looking financial guidance provided.